| First Author | Schnepp RW | Year | 2013 |
| Journal | Cancer Discov | Volume | 3 |
| Issue | 3 | Pages | 255-7 |
| PubMed ID | 23475876 | Mgi Jnum | J:198393 |
| Mgi Id | MGI:5496499 | Doi | 10.1158/2159-8290.CD-13-0018 |
| Citation | Schnepp RW, et al. (2013) Targeting MYCN: a good BET for improving neuroblastoma therapy?. Cancer Discov 3(3):255-7 |
| abstractText | Direct targeting of oncogenic MYC proteins has been an elusive goal of many cancer drug development efforts. In this issue of Cancer Discovery, Stegmaier and colleagues demonstrate that pharmacologically interfering with the bromodomain and extraterminal (BET) class of proteins potently depletes MYCN in neuroblastoma cells, resulting in cellular cytotoxicity and thus providing a novel approach with a potential impact on a previously undruggable major oncogene. |
